by Brenda Baletti, Ph.D., Childrens Health Defense:
The human papillomavirus (HPV) vaccine may increase the prevalence and distribution of some HPV virus strains not targeted by the vaccine — including some strains that are linked to cancer, according to a study published last week in Cell Host & Microbe. But STATNews misleadingly, according to experts, concluded the study showed the vaccine was effective at preventing cancer.
TRUTH LIVES on at https://sgtreport.tv/
The human papillomavirus (HPV) vaccine may increase the prevalence and distribution of some HPV virus strains not targeted by the vaccine — including some strains that are linked to cancer — resulting in unknown and potentially concerning consequences, according to a study published last week in Cell Host & Microbe.
The study was not designed to show that the HPV vaccine prevents cancer or that HPV or cervical cancer screenings need to change, though the authors did include a brief, speculative mention of the potential implications of their findings for future screening.
Yet STATNews, reporting on the study, said the findings showed that the HPV vaccine is so effective at preventing cancers — particularly when both boys and girls are vaccinated — that cancer-screening protocols may need to change.
Kim Mack Rosenberg, Children’s Health Defense (CHD) acting general counsel and co-author of “The HPV Vaccine On Trial: Seeking Justice For A Generation,” told The Defender the STATNews story was misleading:
“The STATNews headline — misguidedly suggesting even less frequent screening — is deeply troubling. Statistics in the U.S. and elsewhere suggest that cervical cancer is on the rise in younger age cohorts where we least expect to see cervical cancer, while continuing to decline in the older populations where cervical cancer historically is diagnosed.
“We know from prior studies that the HPV vaccines already have led to decreased cervical intraepithelial neoplasia/cervical cancer screening at appropriate intervals for young women around the world.
“We have also seen a number of cases in the vaccine injury compensation program in the U.S. (and the multidistrict litigation in federal court) alleging cervical cancer associated with HPV vaccination.”
‘Imminent risk of viral evolutionary responses’ may ‘introduce problems’
The study included approximately 11,000 — not 60,000 as STAT reported — young women born in 1992, 1993 and 1994 from 33 Finnish communities. The researchers divided them into three groups based on their community’s vaccination strategy: gender-neutral HPV vaccination, girls-only vaccination and no vaccination.
Four years after the groups were first offered vaccination (and eight years after for a smaller subset of around 3,600 subjects), the researchers tested for 16 types of genital HPV viruses considered oncogenic (linked to tumor formation) because they are associated with cervical or other cancers. The presence of oncogenic HPV is not the only risk factor for cervical cancer.
There are over 200 strains of the HPV virus, a subset of which are deemed high-risk. Depending on the vaccine, HPV vaccines target only two (Cervavix targets strains 16 and 18), four (Gardasil 4 targets strains 6, 11, 16 and 18) or nine (Gardasil 9, which adds strains 31, 33, 45, 52, 58) of those high-risk strains.
The researchers investigated how different community-level HPV vaccination strategies might change the prevalence of different HPV strains.
They found that in both vaccination groups, four and eight years following vaccination, there was a significant depletion of the high-risk HPV types targeted by the vaccine relative to the non-vaccinated group. The depletion was stronger in the gender-neutral group — when boys had also been vaccinated.
But they also found a higher prevalence of other, lower-risk oncogenic HPV strains than previously existed, particularly in the gender-neutral group. As the vaccine suppressed the targeted strains, the authors explained, other strains moved into the “niche” they formerly occupied.
That means that rather than reducing the incidence of the HPV virus altogether, vaccination changed the distribution of HPV strains, they wrote. Those oncogenic strains not targeted by the vaccine that grew in prevalence are also linked to cancer but at lower rates.
Other studies also have shown that HPV vaccination programs have caused the replacement of the previously most common types of HPVs with rarer types of HPV that also cause cancer.
The authors noted that “the imminent risk of viral evolutionary responses” would diminish the impact of HPV vaccination.
“It is tempting to suggest that an increase of [other oncogenic strains] or the like with increased virulence might cause a risk of HPV-related cancers in the future,” they said.
In other words, new strains that occupy the niche vacated by the vaccine-targeted strains could become more virulent and potentially cancer-causing.
The authors concluded that to control oncogenic HPVs and related cancers, more research on how long-term vaccine use could change the disease evolution is imperative. They said this may have implications for future screening protocols, but did not elaborate.
Rosenberg said the implications are that more rigorous screening protocols may be necessary. She said:
“In ‘HPV Vaccine on Trial,’ my co-authors and I discussed type replacement, a phenomenon found with HPV vaccines and other vaccines.
“The study discussed in the STATNews article actually raises again the specter of type replacement — which should support more rigorous screening protocols, not a lackadaisical, unsupported reduction in screening placing the health of untold numbers of young women at risk.”
Why would ‘type replacement’ matter?
The study authors hypothesized that this strain-type replacement occurs because vaccine-induced immunity reduces the number of people susceptible to the targeted strains and leads to a biased immune response favoring infection by other strains.
Type replacement could also lead to the selection for immune escape variants — new variants that result from the selective pressure on the virus from imperfect vaccination.
Vaccine-favored variants have developed after vaccination for a number of diseases, including hepatitis B, pertussis, Streptococcus pneumoniae, Marek’s disease, malaria and diphtheria.
In some cases, like Marek’s disease and malaria, research shows vaccination led to an increased prevalence of variants with increased virulence. In others, like pertussis, this evolution was linked to the paradoxical reemergence of the disease in highly vaccinated populations.
In other cases, such as Haemophilus influenzae type b, evidence suggested that vaccination caused a milder strain to become more virulent.
Read More @ ChildrensHealthDefense.org
